Eisai Co., Ltd. ESALY
61.51 0.00 (+0.00%)
Jan 30, 2023, 3:59 PM EST
61.00 Day range 63.29
52-week range unavailable
- Market cap
- 17.64B
- Volume
- 331.86K
- Open
- 62.35
- Previous close
- 61.51
- Day's range
- 61.00 – 63.29
- Earnings date
- Feb 2, 2023
No chart data for this range yet.
Next earnings
Feb 2, 2023
Expected Feb 2, 2023. Consensus EPS estimate 0.00.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 2, 2023 | Dec 1, 2022 | 0.00 | — | — | — |
| Nov 7, 2022 | Sep 1, 2022 | 0.00 | — | — | — |
| Aug 5, 2022 | Jun 1, 2022 | 0.00 | — | — | — |
| May 13, 2022 | Mar 1, 2022 | 0.00 | — | — | — |
| Feb 3, 2022 | Dec 1, 2021 | 0.00 | — | — | — |
| Nov 1, 2021 | Sep 1, 2021 | 0.00 | — | — | — |
News
Eisai (OTCMKTS:ESALY) Stock Crosses Below 50 Day Moving Average – Time to Sell? 
Eisai (OTCMKTS:ESALY) Share Price Crosses Below 50 Day Moving Average – Here’s Why 
These Alzheimer's drugs were supposed to revolutionize the way we fight the disease. The reality is more complicated. 
Prothena Reports Non-Competitive Brain Swelling Rates In Early Alzheimer's Study 
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb 
President Trump demands drugmakers slash prices within 60 days 
Alzheimer's drug Leqembi promises to give patients more time, but they face a long road to treatment 
UK patients unlikely to get access to Eisai-Biogen's Alzheimer's drug 
Eisai Co Ltd (ESALF) Q1 2025 Earnings Call Transcript 
Benefit of Eisai and Biogen's Alzheimer's drug increases over time, studies suggest
Your note
Sign in to keep a note on ESALY — it syncs with the Stock Master app.